Considering the CLARITY Phase III study results, cladribine tablets may offer several improvements over existing MS drugs including a simple, short-course annual dosing regimen of either 2 or 4 ...

Other clinical trials have tested a drug called Cladribine, a powerful intravenous chemotherapy drug used for leukemia, in Type II refractory patients. One trial, conducted in the Netherlands, found ...

There’s no news yet on its US list price. Along with other S1P drugs, it will also have to compete with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was ...

Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) prior to conception: * Other anti-CD20 monoclonal antibody: same class as Kesimpta ...

Merck KGaA's recently approved MS pill Mavenclad (cladribine) is also available to NHS patients after the company agreed to only charge for patients that respond to the treatment. Vertex's gene ...

The risk of bladder, brain, cervical, and kidney cancer was significantly increased in MS… A sublingual formulation of cladribine, which is the active ingredient of the approved oral treatment ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis in which you experience relapses of the disease with periods of remission occurring in between. Relapsing-remitting multiple ...

There are many treatments available for MS, many of which can help decrease the frequency and severity of relapses, improve physical function, and ease symptoms caused by the condition. While ...

Langerhans cell histiocytosis (LCH) is a disease caused by clonal expansion of CD1a+/CD207+ cells and is characterized by organ involvement and dysfunction. Treatment of LCH in children is ...

Tech company Century Health has entered into a partnership to organize and clean Nira Medical‘s datasets from more than 3,000 people with multiple sclerosis (MS) to help make clinical data more ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

Background A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet ...